ORIENTBIO Inc. (002630) - Net Assets

Latest as of September 2025: ₩69.62 Billion KRW ≈ $47.18 Million USD

Based on the latest financial reports, ORIENTBIO Inc. (002630) has net assets worth ₩69.62 Billion KRW (≈ $47.18 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩82.15 Billion ≈ $55.67 Million USD) and total liabilities (₩12.53 Billion ≈ $8.49 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of ORIENTBIO Inc. to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩69.62 Billion
% of Total Assets	84.75%
Annual Growth Rate	2.59%
5-Year Change	48.0%
10-Year Change	-21.3%
Growth Volatility	24.19

ORIENTBIO Inc. - Net Assets Trend (2006–2025)

This chart illustrates how ORIENTBIO Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore 002630 total assets for the complete picture of this company's asset base.

Annual Net Assets for ORIENTBIO Inc. (2006–2025)

The table below shows the annual net assets of ORIENTBIO Inc. from 2006 to 2025. For live valuation and market cap data, see 002630 market cap.

Year	Net Assets	Change
2025-03-31	₩71.85 Billion ≈ $48.69 Million	-15.57%
2024-03-31	₩85.10 Billion ≈ $57.67 Million	+19.19%
2023-03-31	₩71.39 Billion ≈ $48.38 Million	-14.18%
2022-03-31	₩83.19 Billion ≈ $56.38 Million	+71.36%
2021-03-31	₩48.55 Billion ≈ $32.90 Million	-6.58%
2020-03-31	₩51.96 Billion ≈ $35.21 Million	-17.05%
2019-03-31	₩62.65 Billion ≈ $42.45 Million	-21.62%
2018-03-31	₩79.92 Billion ≈ $54.16 Million	-18.40%
2017-03-31	₩97.94 Billion ≈ $66.38 Million	+7.29%
2016-03-31	₩91.29 Billion ≈ $61.87 Million	+35.55%
2015-03-31	₩67.35 Billion ≈ $45.64 Million	+8.90%
2014-03-31	₩61.85 Billion ≈ $41.91 Million	-0.71%
2013-03-31	₩62.29 Billion ≈ $42.21 Million	+2.93%
2012-03-31	₩60.51 Billion ≈ $41.01 Million	-7.59%
2011-03-31	₩65.49 Billion ≈ $44.38 Million	+6.03%
2010-03-31	₩61.77 Billion ≈ $41.86 Million	+7.24%
2009-03-31	₩57.60 Billion ≈ $39.03 Million	+52.43%
2008-03-31	₩37.79 Billion ≈ $25.61 Million	-15.77%
2007-03-31	₩44.86 Billion ≈ $30.40 Million	+1.47%
2006-03-31	₩44.21 Billion ≈ $29.96 Million	--

Equity Component Analysis

This analysis shows how different components contribute to ORIENTBIO Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 279135981000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	₩2.79 Billion	3.89%
Other Components	₩69.06 Billion	96.11%
Total Equity	₩71.85 Billion	100.00%

ORIENTBIO Inc. Competitors by Market Cap

The table below lists competitors of ORIENTBIO Inc. ranked by their market capitalization.

Company	Market Cap
Royalty Management Holding Corporation NASDAQ:RMCO	$43.15 Million
Sportshero Ltd AU:SHO	$43.18 Million
Beshom Holdings Bhd KLSE:7668	$43.20 Million
FRIWO AG F:CEA	$43.21 Million
Ekarat Engineering Public Company Limited BK:AKR	$43.13 Million
XTPL SA WAR:XTP	$43.10 Million
Theranexus SA PA:ALTHX	$43.09 Million
AS Pro Kapital Grupp F:17E	$43.08 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ORIENTBIO Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 85,095,979,050 to 71,846,796,270, a change of -13,249,182,780 (-15.6%).
Net loss of 13,194,865,820 reduced equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩-13.19 Billion	-18.37%
Other Changes	₩-54.32 Million	-0.08%
Total Change	₩-	-15.57%

Book Value vs Market Value Analysis

This analysis compares ORIENTBIO Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.89x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.57x to 0.89x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-03-31	₩944.23	₩537.00	x
2018-03-31	₩699.08	₩537.00	x
2019-03-31	₩636.42	₩537.00	x
2020-03-31	₩510.52	₩537.00	x
2021-03-31	₩409.47	₩537.00	x
2022-03-31	₩701.60	₩537.00	x
2023-03-31	₩602.12	₩537.00	x
2024-03-31	₩717.70	₩537.00	x
2025-03-31	₩605.95	₩537.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently ORIENTBIO Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -18.37%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -44.88%
• Asset Turnover: 0.35x
• Equity Multiplier: 1.18x
Recent ROE (-18.37%) is below the historical average (-8.69%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	1.17%	2.35%	0.31x	1.62x	₩-3.96 Billion
2011	7.00%	8.44%	0.57x	1.46x	₩-1.74 Billion
2013	1.60%	1.14%	0.57x	2.49x	₩-4.60 Billion
2014	-17.36%	-11.41%	0.60x	2.54x	₩-15.05 Billion
2015	-3.26%	-1.87%	0.63x	2.77x	₩-7.12 Billion
2016	-3.92%	-2.86%	0.60x	2.29x	₩-10.69 Billion
2017	-27.21%	-17.54%	0.63x	2.46x	₩-26.16 Billion
2018	-26.30%	-11.44%	0.64x	3.60x	₩-19.14 Billion
2019	-30.11%	-64.22%	0.36x	1.30x	₩-25.98 Billion
2020	-20.94%	-28.86%	0.52x	1.39x	₩-16.08 Billion
2021	-31.47%	-29.36%	0.73x	1.47x	₩-20.13 Billion
2022	41.11%	130.15%	0.25x	1.26x	₩25.88 Billion
2023	-17.40%	-43.11%	0.36x	1.14x	₩-19.56 Billion
2024	15.13%	45.96%	0.29x	1.14x	₩4.36 Billion
2025	-18.37%	-44.88%	0.35x	1.18x	₩-20.38 Billion

Industry Comparison

This section compares ORIENTBIO Inc.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $403,126,270,880
Average return on equity (ROE) among peers: 1.07%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
ORIENTBIO Inc. (002630)	₩69.62 Billion	1.17%	0.18x	$43.15 Million
Green Cross (005250)	$1.51 Trillion	0.20%	0.84x	$425.10 Million
Green Cross Holdings Preference Shares (005257)	$1.85 Trillion	1.30%	0.98x	$3.74 Million
Pharmicell (005690)	$51.52 Billion	8.44%	0.23x	$736.42 Million
GeneOne Life Science Inc (011000)	$39.74 Billion	0.00%	0.49x	$49.94 Million
HLB Co. Ltd (028300)	$19.44 Billion	0.00%	0.66x	$5.41 Billion
Daesung Microbiological Labs. Co. Ltd (036480)	$37.00 Billion	2.34%	0.69x	$19.29 Million
Seoulin Bioscience Co.Ltd (038070)	$51.49 Billion	4.00%	0.38x	$37.92 Million
Hyundai Bioscience Co. Ltd (048410)	$58.24 Billion	3.27%	0.77x	$872.13 Million
iNtRON Biotechnology Inc (048530)	$11.93 Billion	-9.93%	0.65x	$77.34 Million

About ORIENTBIO Inc.

KO:002630 Korea Biotechnology

Market Cap

$43.15 Million

₩63.67 Billion KRW

Market Cap Rank

#22426 Global

#1516 in Korea

Share Price

₩537.00

Change (1 day)

-1.29%

52-Week Range

₩524.00 - ₩1814.00

All Time High

₩6770.89